MARKET WIREYahoo • 2d ago
Hims & Hers Health, Inc. (HIMS) Gains As Market Dips: What You Should KnowIn the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $29.69, marking a +1.24% move from the previous day.
Why HIMS Stock advanced +1.19% Today — RQD Quant Desk Flash
$29.67 +1.19% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
Hims & Hers Health Inc. (HIMS) carries a Roarable Rating of C (Hold) with 63/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
ROARABLE C • HOLD / WATCH
Cap $6.92B
INTERACTIVE SCENARIO DECK:
RQD QUANT TACHOMETERHOLD / WATCH • C
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw C · Rk C-
Each axis scored 0–20
12M PRICE TARGET CONE+2.3% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HIMS)Realized 20D OHLCV Swing Band: ±12.5%
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why HIMS Stock advanced +1.19% Today — RQD Quant Desk Flash
Hims & Hers Health Inc. (HIMS) advanced +1.19% to $29.67, trading at 46% of its 52-week range ($13.74 – $48.34). Solid 74% profit margin (8% return on capital), mixed timing at 54x P/E—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 46% of its 52-week range ($13.74 – $48.34) with RSI-14 at 53.1 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $29.67 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable C (Hold) backed by 73.8% gross margin and $194.4M annual free cash flow.
Live HIMS Headlines & Catalysts
CATALYSTYahoo • 2d ago
Teladoc Soars 11% on Q3 Beat and Raised Outlook as “Insurance Revenue Exceeded Our Expectations”Key TakeawaysTeladoc Health rose 11% after its third-quarter adjusted EBITDA beat guidance, rising 14% to $79. 4 million.
CATALYSTYahoo • 3d ago
Eli Lilly Soars 5% as Mounjaro and Zepbound Demand Drives $5.5 Billion Guidance RaiseKey TakeawaysEli Lilly shares rose 5% after third-quarter revenue jumped 39% to $24. 4 billion and it raised 2026 revenue guidance by $5.
CATALYSTYahoo • 3d ago
Eli Lilly Jumps 8% as Strong Quarter Lifts Revenue Outlook; Novo Nordisk Ticks Up, Viking Therapeutics EasesEli Lilly (NYSE:LLY) just extended its lead in obesity drugs, and its newer cancer, immunology and neuroscience products are starting to matter, while the rest of the glucagon-like peptide-1 (GLP-1) group is barely movin
CATALYSTYahoo • 3d ago
HIMS Stock Jumps 5% After HHS Temporarily Clears Compounding Of Six PeptidesHHS said it will not go after state-licensed pharmacies, federal facilities, or licensed doctors for compounding six peptides—BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500.
CATALYSTYahoo • 3d ago
Hims & Hers Jumped 6% as RFK Jr.’s HHS Uses “Enforcement Discretion” to Open Peptide CompoundingKey TakeawaysHims & Hers shares rose 6% today after HHS said it won’t act against qualifying pharmacies compounding six unapproved peptides while it writes a formal rule. Hims has said it’s waiting for final FDA rules be
CATALYSTYahoo • 3d ago
Hims Stock Surges After RFK Jr. Eases Access To Unapproved PeptidesHims stock popped Wednesday after RFK Jr. circumvented the FDA, giving a green light to some unapproved peptides.
RISK WATCHYahoo • 4d ago
Can Hims & Hers Stock Fall 30%?For questions about this article or underlying research, email help@trefis.com.
MARKET WIREBenzinga • 4d ago
U.S. Department Of Health And Human Services Announces Availability Of Enforcement Discretion Policy Regarding 503a Compounding Using Certain Peptide Bulk Drug Substances; Will Not Enforce Against Pharmacies, Federal Facilities Or Physicians Compounding Drugs Using Peptide Bulk Substances Pending Rulemaking; Interim Policy Permits Peptide Compounding Pending Final Rulemaking On 503a Bulk Drug Substances Listhttps://www.federalregister.gov/public-inspection/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances
MARKET WIREYahoo • 5d ago
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to KnowHims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (HIMS Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 1,540+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
HIMS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +8.80%⚡ TESTING RESISTANCE
2026-11-01O $29.32H $29.67L $29.32C $29.67VOL 7.52M
RES: $30.65SUP: $26.79SMA50: $28.96SMA200: $27.02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
HIMS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
38.4%/yr Implied 5Y Growth
vs. +59.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on HIMS today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for HIMS. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for HIMS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HIMS)
Health Care Rank #102 of 188
⚔️ CHE vs HIMS Full Matrix →
1. Head-to-Head Health Care Peer Comparison (HIMS vs. CHE, OPCH, BTSG, TDOC)
Industry: Medical/Nursing Services (5 Tracked Issuers)Across 188 tracked Health Care securities in the Roarable RQD universe, Hims & Hers Health Inc. (HIMS) ranks #102 by composite RQD confidence (63/100, grade C) and #137 by equity capitalization ($6.92B). Within this direct 5-issuer industry benchmark cohort, OPCH leads on earnings valuation at 23.0x trailing P/E, while CHE leads on capital efficiency and profitability with 23.4% ROIC and 32.5% gross margin. CHE currently holds the highest overall quantitative score in the immediate peer group at 84/100 (A-) compared with HIMS at 63/100 (C).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| HIMS
ACTIVE
Hims & Hers Health Inc. | C | 63/100 | 53.9x | 73.8% | 8.4% | +1.19% | $6.92B | Benchmark Subject |
| CHE Chemed Corp | A- | 84/100 | — | 32.5% | 23.4% | +1.61% | $7.08B | /che-vs-hims → |
| OPCH Option Care Health Inc. | B | 75/100 | 23.0x | 19.3% | 11.9% | +1.79% | $4.77B | /opch-vs-hims → |
| BTSG BrightSpring Health Services Inc. | C | 62/100 | 63.0x | 11.8% | 5.5% | +1.28% | $11.92B | /btsg-vs-hims → |
| TDOC Teladoc Health Inc. | D+ | 56/100 | — | — | -17.0% | +26.89% | $1.59B | /tdoc-vs-hims → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001773751In its most recent audited fiscal period (FY2025, filed 2025-12-31), Hims & Hers Health Inc. (HIMS) reported GAAP revenue of $2.35B (+59.0% vs. FY2024 revenue of $1.48B , and +169.2% cumulative change since FY2023) , GAAP net income of $128.4M, operating cash flow of $300.0M, and free cash flow of $194.4M (+5.3% YoY). On the balance sheet, HIMS closed FY2025 with $2.15B in total assets against $726.2M in total debt (Altman Z-Score: 3.95, Piotroski F-Score: 8/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $2.35B | $128.4M | $300.0M | $194.4M | $2.15B | $726.2M |
| FY2024 (FY) | 2024-12-31 | $1.48B | $126.0M | $251.1M | $184.6M | $707.5M | $103.9M |
| FY2023 (FY) | 2023-12-31 | $872.0M | -$23.5M | $73.5M | $34.2M | $3.81B | $890.9M |
3. HIMS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs HIMS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Hims & Hers Health Inc. (NYSE: HIMS) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 63/100 at a spot price of $29.67 (+1.19% 1D, market cap $6.92B). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 11/20. Across 188 tracked Health Care issuers, HIMS ranks #102 in composite RQD confidence.
How does HIMS compare to CHE and OPCH in the Health Care sector?
Within the Health Care sector (Medical/Nursing Services), HIMS carries a Roarable C (63/100 RQD), trailing P/E of 53.9x, gross margin of 73.8%, and ROIC of 8.4%. By comparison, CHE (Chemed Corp) holds a A- grade (84/100 RQD, P/E N/A, ROIC 23.4%, cap $7.08B) and OPCH (Option Care Health Inc.) posts a B grade (75/100 RQD, P/E 23.0x, ROIC 11.9%, cap $4.77B). Among the 5-stock peer group, OPCH leads on earnings multiple (23.0x) while CHE leads on capital efficiency (23.4% ROIC).
What are the biggest fundamental strengths and SEC risk factors for HIMS?
Per HIMS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001773751), Hims & Hers Health Inc. generated $2.35B in revenue (+59.0% YoY), $128.4M in net income, and $194.4M in free cash flow against $2.15B in total assets and $726.2M in total debt. Key quantitative strengths: Strong cash generator (74% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is HIMS trading relative to its 50-day, 200-day, and 52-week technical levels?
HIMS last traded at $29.67 (+1.19% on volume of 7,519,701 shares), positioning the stock +2.45% above its 50-day simple moving average ($28.96) and +9.81% above its 200-day simple moving average ($27.02). Across its 52-week range of $13.74 to $48.34, HIMS sits at the 46.0% percentile with a 14-day RSI of 53.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($25.96 to $33.38).
HIMS Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is HIMS stock moving today?
Why HIMS Stock advanced +1.19% Today — RQD Quant Desk Flash. Solid 74% profit margin (8% return on capital), mixed timing at 54x P/E—hold if owned, no rush to chase.